Results 91 to 100 of about 2,036 (191)

Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season

Vaccines
Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life.
Alessandra Consolati, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, Salvatore Bongiorno   +6 more
doaj   +1 more source

Single-dose nirsevimab prevents RSV infection [PDF]

The Journal of Pediatrics, 2021
Shabir A, Madhi, Eric A F, Simões
openaire   +2 more sources

β‐Lactamase‐Producing Haemophilus influenzae Pneumonia in a 1‐Month‐Old Infant With Respiratory Syncytial Virus Bronchiolitis

Journal of General and Family Medicine, Volume 27, Issue 3, May 2026.
Kazumasa Zensho, Naoki Nojima, Ryoma Hino, Naohi Isse   +3 more
wiley   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study

BMJ Public Health
Introduction Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants.
Miguel Angel Casado, Ruth Gil-Prieto, Jaime Pérez-Martín, Ariadna Díaz Aguiló, Samira Soudani, Leticia Platero-Alonso, Juan Luis López-Belmonte, Alberto de la Cuadra-Grande, Javier Álvarez Aldean   +8 more
doaj   +1 more source

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025

Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged \u3c year) in the United States.
Orzel-Lockwood, Amber O., Schuster, Jennifer E., al, et, Zerr, Danielle M., Gertz, Shira J., Irby, Katherine, Payne, Amanda B., Calixte, Jemima M., Chiotos, Kathleen, Crandall, Hillary, Nofziger, Ryan A., Hume, Janet R., Simeone, Regina M., Kamidani, Satoshi, Shein, Steven L., Halasa, Natasha B., Maddux, Aline B., Michelson, Kelly N., Newhams, Margaret M., Bhumbra, Samina S., Chauhan, Jigar C., Guzman-Cottrill, Judith A., Coates, Bria M., Staat, Mary Allen, Kong, Michele, Martin, Lora M., Bradford, Tamara T., Cameron, Melissa A., Zambrano, Laura D.   +28 more
core   +1 more source

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Human Vaccines & Immunotherapeutics
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Narmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, Alberto Malvar-Pintos, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres   +21 more
doaj   +1 more source

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab

Pediatric Infectious Disease Journal
Background: Nirsevimab is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Although nucleic acid detection by polymerase chain reaction is primarily utilized for the clinical diagnosis of RSV, antigen detection is still routinely used and ...
Sarah R. Sincero, Kelly Ann Mahool, Emma Schaefer, Carolina S. Caceres, Elizabeth J. Kelly, Deidre Wilkins, Kevin M. Tuffy   +6 more
openaire   +2 more sources

Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was ...
Enrico Valletta, Anthea Mariani, Claudio Cafagno, Désirée Caselli, Francesco Accomando, Claudia Rossini, Martina Fornaro, Giulia Marozzi, Melodie O. Aricò, Daniela Trotta, Letizia Lorusso, Maurizio Aricò   +11 more
core   +1 more source

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

Importance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer\u27s maternal RSV vaccine.
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Paden, Clinton, Clopper, Benjamin R, Thornburg, Natalie J, Dawood, Fatimah S, Sahni, Leila C, Englund, Janet A, Atherton, Lydia, Schlaudecker, Elizabeth P, Schuster, Jennifer E, Michaels, Marian G, Aggarwal, Megha, Stewart, Laura S, Halasa, Natasha B, Staat, Mary A, Piedra, Pedro A, Selvarangan, Rangaraj, Roychoudhury, Pavitra, Derado, Gordana, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Tannis, Ayzsa, Moline, Heidi L, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, New Vaccine Surveillance Network Collaborators   +30 more
core   +1 more source

Analysis of Beyfortus^® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

Current Issues in Molecular Biology
Respiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections.
Hélène Banoun
doaj   +1 more source